After several European Countries voiced their concerns over COVID-19 vaccine AstraZeneca forming blood clots after inoculation, India said that they are looking at all ‘serious’ side effects, a leading media house reported. Dr NK Arora, a member of ICMR’s National Task Force for coronavirus, said that the ‘Adverse Event’, following the immunisation will be monitored for both Covishield and Covaxin.

Dr Arora said that they are not looking at any particular vaccine at the moment but will make the analysis available when anything is reported.

“We are not looking at any particular vaccine at the moment. When the analysis is available, it will be reported, according to the vaccine, if there is any cause for concern,” AFP quoted Dr Arora as saying.

“We are closely looking at all the AEFIs (Adverse Event Following immunisation) for both vaccines – Covaxin and Covishied,” he further added.

He went on to further explain that there are two types of AEFIs – mild and serious.

Earlier, the EU’s largest countries joined a stream of states halting their rollouts of AstraZeneca jabs. Both organisations – EU and WHO -will hold special meetings this week to discuss the developments.

The three largest EU countries — Germany, Italy and France — all paused rollouts on Monday and were later joined by Spain, Portugal, Slovenia and Latvia.

The suspensions were not limited to Europe, with Indonesia also announcing a delay to its rollout of the jab.

However, the WHO insisted countries should keep using the vaccine, adding that it had scheduled a meeting of its experts on Tuesday to discuss the vaccine’s safety.